News articles about Zosano Pharma (NASDAQ:ZSAN) have been trending positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.9916760903204 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Two sizzlers stock’s are not to be missed: Zosano Pharma Corporation, (NASDAQ: ZSAN), KB Home, (NYSE: KBH); (tradingnewsnow.com)
- Clue to Identify In Play Stock (Relative Volume) – Zosano Pharma Corporation (NASDAQ: ZSAN) (alphabetastock.com)
- Zosano Pharma to Host Conference Call to Provide Operational Update (feeds.benzinga.com)
- Stock With Escalations: Zosano Pharma Corporation (NASDAQ:ZSAN) (thestreetpoint.com)
- Mid-Day Market Update: Dow Rises Over 1%; Zosano Pharma Shares Plummet (fxstreet.com)
NASDAQ:ZSAN traded down $0.02 during midday trading on Monday, hitting $5.02. 1,019,777 shares of the company were exchanged, compared to its average volume of 1,276,631. The firm has a market capitalization of $9.94, a P/E ratio of -0.30 and a beta of 1.92. Zosano Pharma has a fifty-two week low of $3.61 and a fifty-two week high of $38.60.
Separately, ValuEngine lowered shares of Zosano Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th.
In related news, major shareholder Amzak Capital Management, Llc sold 88,281 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $8.40, for a total transaction of $741,560.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.83% of the stock is owned by insiders.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.